Peter Blume-Jensen, Acrivon Therapeutics CEO
November 11, 2021 09:34 AM EST
Financing

Acrivon bags a megaround to ad­vance an old Eli Lil­ly pro­gram, 5 months af­ter launch. Is an IPO far be­hind?

Max Gelman

Senior Editor

Not five months af­ter launch­ing with an old Eli Lil­ly as­set, Acrivon Ther­a­peu­tics is al­ready up­ping the ante.

The Cam­bridge, MA-based biotech pulled in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times